Clinical relapse · SSNS in children
Alkylating agents probably leads to lower relapse at 6 to 12 months compared with steroids, placebo or both (moderate certainty).
2 findings from 1 review
Frequent relapses · SSNS in children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean relapse rate/patient/month · SSNS in children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
CPA: leucopenia · SSNS in children
Alkylating agents led to higher CPA: leucopenia compared with steroids, placebo or both; GRADE not reported.
1 finding from 1 review
RR 10.63 [1.45, 78.05]
Studies not reported
GRADE not reported
Chlorambucil: leucopenia · SSNS in children
Alkylating agents showed no clear difference in chlorambucil: leucopenia compared with steroids, placebo or both; GRADE not reported.
1 finding from 1 review
RR 2.5 [0.11, 54.87]
Studies not reported
GRADE not reported
Adverse effects: moderate to severe Infusion reactions · SSNS in children
Rituximab may leads to higher adverse effects: moderate to severe Infusion reactions compared with placebo or control (low certainty).
1 finding from 1 review
Clinical relapse · SSNS in children
Intravenous may leads to lower relapse at 6 months compared with oral cyclophosphamide (low certainty).
1 finding from 1 review
Continuing frequently relapsing or steroid‐dependent SSNS at 6 months · SSNS in children
Intravenous may leads to lower continuing frequently‐relapsing or steroid‐dependent SSNS at 6 months compared with oral cyclophosphamide (low certainty).
1 finding from 1 review
Relapse · SSNS in children
Intravenous showed no clear difference in relapse at end of study compared with oral cyclophosphamide (low certainty).
1 finding from 1 review
Mean relapse rate/patient/month · SSNS in children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: leucopenia · SSNS in children
Intravenous showed no clear difference in adverse events: leucopenia compared with oral cyclophosphamide (low certainty).
1 finding from 1 review
Adverse events: hair loss · SSNS in children
Intravenous showed no clear difference in adverse events: hair loss compared with oral cyclophosphamide (low certainty).
1 finding from 1 review
Adverse events: all infections · SSNS in children
Intravenous may leads to lower adverse events: all infections compared with oral cyclophosphamide (low certainty).
1 finding from 1 review
Adverse event nausea and vomiting (0 to 24 hours) · SSNS in children
It is very uncertain whether intravenous changes adverse events: nausea and vomiting compared with oral cyclophosphamide (very low certainty).
1 finding from 1 review
Relapse · SSNS in children
Cyclophosphamide showed no clear difference in relapse at 12 months compared with chlorambucil (low certainty).
1 finding from 1 review
Clinical relapse · SSNS in children
Cyclophosphamide showed no clear difference in relapse at 24 months compared with chlorambucil (low certainty).
1 finding from 1 review
Adverse effects: severe infection · SSNS in children
Rituximab showed no clear difference in adverse effects: severe infection compared with placebo or control (low certainty).
1 finding from 1 review
Frequent relapses · SSNS in children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean relapse rate/patient/month · SSNS in children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: lymphopenia · SSNS in children
Cyclophosphamide may leads to lower adverse effects: lymphopenia compared with chlorambucil (low certainty).
1 finding from 1 review